Tuberculosis Chemotherapy

This publication has 6 references indexed in Scilit:

• Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis
  American Journal of Respiratory and Critical Care Medicine, 2003
• American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America
  American Journal of Respiratory and Critical Care Medicine, 2003
• Short-Course Rifamycin and Pyrazinamide Treatment for Latent Tuberculosis Infection in Patients with HIV Infection
  Chest, 2002
• Safety and Tolerability of Intermittent Rifampin/Pyrazinamide for the Treatment of Latent Tuberculosis Infection in Prisoners
  JAMA, 2002
• Hepatotoxicity Associated With Isoniazid Preventive Therapy
  JAMA, 1999
• Controlled Trial of 2, 4, and 6 Months of Pyrazinamide in 6-Month, Three-Times-Weekly Regimens for Smear-positive Pulmonary Tuberculosis, Including an Assessment of a Combined Preparation of Isoniazid, Rifampin, and Pyrazinamide: Results at 30 Months
  American Review of Respiratory Disease, 1991